Outsourced Pharma Capacity Update Videos - Large Molecule
-
Cytovance Capabilities Update October 2026: Large Molecule
11/3/2026
Move biologics from research and development toward commercialization with integrated development, analytics, scalable GMP manufacturing, and early-phase fill-finish capabilities.
-
Lonza Capabilities Update October 2026: Large Molecule
11/2/2026
Ben Neunstoecklin, Director of Commercial Development, provides an overview of biologics drug substance manufacturing capabilities and global network capacity that supports customer programs from development through commercial supply.
-
Novartis Capabilities Update October 2026: Large Molecule
10/28/2026
Reliable biologics manufacturing starts with experienced teams, proven tech transfer, and global capacity that scales from clinic to commercial.
-
Coriolis Pharma Capabilities Update October 2026: Large Molecule
10/28/2026
Integrated drug product development helps biopharma teams identify risks early, optimize formulation and manufacturing, and create stable, scalable biologics ready for clinical and commercial success.
-
3PBiovian Capabilities Update October 2026: Large Molecule
10/28/2026
Integrated CDMO services for biologics and advanced therapies, offering plasmid DNA, viral vectors, fill-finish, and scalable manufacturing from development through commercialization.
-
Rentschler Biopharma Capabilities Update July 2026: Large Molecule
8/7/2026
At Rentschler Biopharma, we help biopharma innovators advance complex large molecule programs from development through commercial manufacturing.
-
Avid Bioservices Capabilities Update July 2026: Large Molecule
8/7/2026
Discover how integrated development and manufacturing can reduce risk, speed timelines, and support seamless progression from early development to commercial production.
-
Samsung Biologics Capabilities Update July 2026: Large Molecule
8/6/2026
We offer end-to-end CDMO services across drug substance, drug product, ADC, mRNA, and organoid modalities, with 845,000L capacity and a 99% batch success rate. Evaluate your multi-plant sourcing framework now.
-
KBI BioPharma Capabilities Update July 2026: Large Molecule
8/3/2026
Combining targeted transposon tech with stable bulk pool generation accelerates cell line development, enabling early material production and fast-tracking candidate selection for clinical entry.
-
AbbVie Capabilities Update July 2026: Large Molecule
8/3/2026
Integrated manufacturing networks de-risk biopharmaceutical scale-up. Flexible mammalian platforms and advanced ADC conjugation ensure strict quality standards and long-term commercial supply.